Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood. 2008;112(8):3107–14. 18. Facon Proteasome assay T, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209–18. 19. Hulin C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
J Clin Oncol. 2009;27(22):3664–70.PubMedCrossRef 20. Rajkmar SV, et al. ASH 2008 joint ASH/ASCO symposium. 21. Dimopoulos MA, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen
for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112–7.PubMedCrossRef 22. Garcia-Sanz R, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4):856–63.PubMedCrossRef 23. Kyriakou C, Selleckchem RG-7388 et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129(6):763–70.PubMedCrossRef 24. Palumbo A, et al. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60. 25. Ladetto M, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in
patients with autografted Adenosine triphosphate myeloma. J Clin Oncol. 2010;28(12):2077–84. 26. Cave M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9–19. 27. Abderrahman A, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to check details double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805–10. 28. Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71. 29. Suzuki K, et al. Maintenance therapy of bortezomib-dexa (BzDx) for multiple myeloma. Clin Hematol. 2010;51(9):1181. 30. Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.PubMedCrossRef 31. Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–69.PubMedCrossRef 32. Reece DE, et al. ASH2010 Poster #1877. 33. Abe Y, Suzuki K, et al. Abstract PS-2-26 (1264) 498. Japan Society of Hematology; 2011. 34. Treatment guidance of multiple myeloma. 2nd ed. Japanese Society of Myeloma; 2008. 35. Blade J, et al.